Literature DB >> 16563504

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

Ruben A Mesa1, Heather Powell, Terra Lasho, Gordon Dewald, Rebecca McClure, Ayalew Tefferi.   

Abstract

Amongst 42 consecutive patients with leukemic transformation (LT) from myelofibrosis with myeloid metaplasia (MMM) 72% carried the JAK2(V617F) mutation. The mutation was observed at expected frequencies in all subtypes of MMM and acute myeloid leukemia. Although the patients with the mutation were younger and had a shorter interval to LT there was no difference in survival. Additionally, both the lack of mutation status progression in serial analysis (available in nine patients) and the low frequency of patients with high mutated allele burden suggest that LT arising from MMM is probably not dependent on changes in JAK2(V617F) mutation status.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563504     DOI: 10.1016/j.leukres.2006.01.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Authors:  John Mascarenhas; Mark L Heaney; Vesna Najfeld; Elizabeth Hexner; Omar Abdel-Wahab; Raajit Rampal; Farhad Ravandi; Bruce Petersen; Gail Roboz; Eric Feldman; Nikolai Podoltsev; Dan Douer; Ross Levine; Martin Tallman; Ronald Hoffman
Journal:  Leuk Res       Date:  2012-08-28       Impact factor: 3.156

Review 2.  Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

Authors:  Madappa N Kundranda; Raoul Tibes; Ruben A Mesa
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 3.  Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Rev Anticancer Ther       Date:  2009-05       Impact factor: 4.512

4.  JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.

Authors:  Giovanni Barosi; Valentina Poletto; Margherita Massa; Rita Campanelli; Laura Villani; Elisa Bonetti; Gianluca Viarengo; Paolo Catarsi; Catherine Klersy; Vittorio Rosti
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

5.  Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Biologics       Date:  2007-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.